No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PFE240719C29500
- 0.25
- +0.10+66.67%
15min DelayTrading Jul 16 15:09 ET
0.32High0.15Low
0.17Open0.15Pre Close12.73K Volume10.40K Open Interest29.50Strike Price303.00KTurnover23.50%IV1.00%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.4654Delta0.5955Gamma111.15Leverage Ratio-0.0442Theta0.0013Rho51.73Eff Leverage0.0113Vega
Intraday
- 5D
- Daily
News
Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt
3 Compelling Reasons to Own Pfizer (NYSE:PFE) Stock
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Pfizer Options Spot-On: On July 15th, 127.16K Contracts Were Traded, With 2.92 Million Open Interest
On July 15th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 127.16K options for the day, of which put options accounted for 39.0% of the total transactions, and call
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free
Comments
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
Big potiental for Russell 2000, REITs & Bond markets in second half year of 2024.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
AI stocks may be struggling in short term but fundamentals are still very strong. A little pullback is normal.
loading...
13
3
Morning Movers
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
Gapping up
$Costco(COST.US$ shares saw an increase of nearly 1.34% as the company announced its first membership fee increase since 2017, raising the cost of its annual membership in the U.S. and Canada by $5 and its higher-tier plan by $10.
$Pfizer(PFE.US$ 's stock went up nearly 2.8% following the company's announcement that it will proceed with the development of a once-daily version of its weight loss pill, ...
39
6
$Pfizer(PFE.US$Pfizer Moves Forward With Once-Daily Weight Loss Pill
Read more